Recombinant human III-type collagen as well as expression method and application thereof
The invention discloses recombinant human collagen III produced by using escherichia coli and an expression method and application of the recombinant human collagen III, and belongs to the technical field of genetic engineering and bioengineering. According to the invention, collagen structure prediction is carried out through AlphaFld2, a peptide fragment composed of 579-608 amino acid residues in a natural human III-type collagen sequence is selected to form a collagen monomer, and monomers with different expression numbers are repeatedly connected in series, so that the collagen monomer has a stable triple-helical structure, and the collagen monomer has a stable triple-helical structure. Monomers with different repetition numbers are transformed into Escherichia coli host bacteria to prepare the recombinant human-derived III-type collagen, and the recombinant human-derived III-type collagen with high purity and good biological activity is obtained, can be widely applied to the industries of biomedical instruments and cosmetics, and has a good application prospect..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 17. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHENG LIHUI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-10-17, Last update posted on www.tib.eu: 2024-01-22, Last updated: 2024-01-26 |
|---|
| Patentnummer: |
CN116891525 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA018947921 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA018947921 | ||
| 003 | DE-627 | ||
| 005 | 20240126102253.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240119s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA018947921 | ||
| 035 | |a (EPA)CN116891525 | ||
| 035 | |a (EPA)88314527 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHENG LIHUI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recombinant human III-type collagen as well as expression method and application thereof |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-10-17, Last update posted on www.tib.eu: 2024-01-22, Last updated: 2024-01-26 | ||
| 520 | |a The invention discloses recombinant human collagen III produced by using escherichia coli and an expression method and application of the recombinant human collagen III, and belongs to the technical field of genetic engineering and bioengineering. According to the invention, collagen structure prediction is carried out through AlphaFld2, a peptide fragment composed of 579-608 amino acid residues in a natural human III-type collagen sequence is selected to form a collagen monomer, and monomers with different expression numbers are repeatedly connected in series, so that the collagen monomer has a stable triple-helical structure, and the collagen monomer has a stable triple-helical structure. Monomers with different repetition numbers are transformed into Escherichia coli host bacteria to prepare the recombinant human-derived III-type collagen, and the recombinant human-derived III-type collagen with high purity and good biological activity is obtained, can be widely applied to the industries of biomedical instruments and cosmetics, and has a good application prospect. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61L: Methods or apparatus for sterilising materials or objects in general; disinfection, sterilisation, or deodorisation of air; chemical aspects of bandages, dressings, absorbent pads, or surgical articles; materials for bandages, dressings, absorbent pads, or surgical articles (preservation of bodies or disinfecting characterised by the agent employed a01n;preserving, e.g. sterilising, food or foodstuffs a23;preparations for medical, dental or toilet purposes a61k) | |
| 650 | 4 | |a C12N: Microorganisms or enzymes; compositions thereof; propagating, preserving, or maintaining microorganisms; mutation or genetic engineering; culture media (microbiological testing media c12q0001000000) | |
| 650 | 4 | |a C07K: Peptides (peptides containing β-lactam rings c07d;cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, c07d;ergot alkaloids of the cyclic peptide type c07d0519020000; single cell proteins, enzymes c12n;genetic engineering processes for obtaining peptides c12n0015000000) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a med | |
| 650 | 4 | |a C12R: Indexing scheme associated with subclasses c12c-c12q, relating to microorganisms | |
| 650 | 4 | |a A61Q: Specific use of cosmetics or similar toilet preparations | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a CHEN XUEJUN |4 aut | |
| 700 | 0 | |a HUANG JING |4 aut | |
| 700 | 0 | |a GAO JIA |4 aut | |
| 700 | 0 | |a WU JIAJING |4 aut | |
| 700 | 0 | |a XU HAO |4 aut | |
| 700 | 0 | |a ZHANG ZHENG |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 17. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:17 |g month:10 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88314527/publication/CN116891525A1?q=CN116891525 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 936 | u | w | |j 2023 |b 17 |c 10 |
| 951 | |a AR | ||
| 952 | |j 2023 |b 17 |c 10 | ||